Series A · Biotech
Kasvu Therapeutics raises €30m Series A for KTX-0141 development
Hadean Ventures led the round as Kasvu prepares studies ahead of planned Phase 1/1b trials in major depressive disorder.
Preparing for clinical development in 2027
Hadean Ventures led Kasvu’s €30 million Series A, with Tesi, Innovestor Life Science Fund, Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments and Helsinki University Funds participating.
The capital will support IND/CTA-enabling work and development of KTX-0141 through Phase 1/1b studies for major depressive disorder. At the announcement, Kasvu planned to begin clinical development in the second half of 2027.
Use of funds
Support IND/CTA-enabling activities
Advance lead candidate KTX-0141 through Phase 1/1b trials for major depressive disorder
Funding history
Series A · This round€30M